Quote "If the data from either the M2M or severe
Post# of 148158
"If the data from either the M2M or severe trial can even be interpreted as not good, then the stock will pull back to the $1-2 range and uplisting will not be possible"
CI what is your educated guess or opinion on what the forthcoming data results will show? As far as being good to not good or interpreted as not good? 50/50 good/ng, 60/40 good/ng? What are you thinking personally?
Read More: https://investorshangout.com/post/view?id=5828148#ixzz6SJTVyGXU